USER ID:
PASSWORD:
Course Overview
Learning Objectives
Upon completion of this activity, participants should be able to:
Explain the debate over whether levodopa is potentially neurotoxic to remaining dopaminergic neurons in Parkinson’s disease
Recognize the range of motor complications caused by levodopa and the mechanism responsible for their development
Recognize the therapeutic usefulness of levodopa in the treatment of Parkinson’s disease
Contents
Opening Remarks and Program Overview - Peter Jenner, BPharm, PhD, DSc
Levodopa: Is It Toxic? Stanley Fahn, MD
Levodopa: How Does It Cause Motor Complications? José A. Obeso, MD,PhD
A Rationale for the Early Use of Carbidopa/Levodopa/Entacapone Fabrizio Stocchi, MD, PhD
Panel Discussion
(c) 2006 The
Movement
Disorder Society & The Center for Advanced Medical Education. All rights reserved.
Privacy Statement
